ライフサイエンスコーパス: dimercaptosuccinic

1 (99m)Tc-labeled dimercaptosuccinic acid ((99m)Tc-DMSA) accumulates in th

2 Serial technetium-99m-labeled dimercaptosuccinic acid ((99m)Tc-DMSA) renal scintigraph

3 renal parenchymal disease on (99m)Technetium-dimercaptosuccinic acid ((99m)Tc-DMSA) scintigraphy.

4 We also did a metastable 99mTc-labelled dimercaptosuccinic acid (DMSA) assay and contrast cystog

5 immersion into aqueous solutions of meso-2,3-dimercaptosuccinic acid (DMSA) at increasing concentrati

6 to-1-propanesulfonic acid (DMPS) or meso-2,3-dimercaptosuccinic acid (DMSA) caused a significant redu

7 One trial (n = 780) of dimercaptosuccinic acid (DMSA) chelation therapy found r

8 Pyronin Y (PY) and chelating agent meso-2,3-dimercaptosuccinic acid (DMSA) for the simultaneous dete

9 Renal cortical imaging with 99mTc-dimercaptosuccinic acid (DMSA) has become the imaging te

10 In this work, renal imaging using (99m)Tc-dimercaptosuccinic acid (DMSA) projects are presented as

11 he newborn babies soon after delivery, and a dimercaptosuccinic acid (DMSA) radioisotope scan at 3 mo

12 toacetyltriglycine (MAG3) renograms, (99m)Tc-dimercaptosuccinic acid (DMSA) renal cortical scans, (99

13 Quantitative 99mTc-dimercaptosuccinic acid (DMSA) renal uptake was studied

14 ictive factor for areas of lack of uptake on dimercaptosuccinic acid (DMSA) scans (P < 0.01).

15 eiving kidney transplants had early and late dimercaptosuccinic acid (DMSA) scans to detect acquired

16 year later, ultrasonography, technetium 99m-dimercaptosuccinic acid (DMSA) scintigraphy, contrast ma

17 enal length measurements obtained with 99mTc-dimercaptosuccinic acid (DMSA) SPECT.

18 ciations between blood lead, tibia lead, and dimercaptosuccinic acid (DMSA)-chelatable lead and measu

19 cificity for APN were compared with those of dimercaptosuccinic acid (DMSA).

20 ully addressed by complexation with meso-2,3-dimercaptosuccinic acid (DMSA).

21 he results were compared with the results of dimercaptosuccinic acid (DMSA, as used drug).

22 treatment with the oral chelating agent 2,3-dimercaptosuccinic acid (DMSA, succimer).

23 These oral chelators, meso-2,3-dimercaptosuccinic acid and sodium 2,3-dimercapto-1-prop

24 cated in organic mercury exposures, meso-2,3-dimercaptosuccinic acid and sodium 2,3-dimercapto-1-prop

25 exposed animals with the chelating agent 2,3-dimercaptosuccinic acid completely reversed the effect o

26 The As(III) chelator dimercaptosuccinic acid did not block the transfer from

27 ; renal scanning with technetium-99m-labeled dimercaptosuccinic acid has also been endorsed by other

28 of photopenia plus contour change on a late dimercaptosuccinic acid renal scan (obtained at study ex

29 rences (SFD) were quantified with technetium-dimercaptosuccinic acid renography.

30 Dimercaptosuccinic acid scans provide important informat

31 Ultrasounds and dimercaptosuccinic acid scintigraphies (DMSA) of all pat

32 ify patients at risk for kidney damage, with dimercaptosuccinic acid scintigraphy as the reference me

33 phantoms have been used to simulate (99m)Tc-dimercaptosuccinic acid SPECT images.

34 thiol-based compounds dimercaptopropanol and dimercaptosuccinic acid suppressed toxicity in both HD c

35 A new drug, DMSA (meso 2,3-dimercaptosuccinic acid) has been approved for oral chel

36 luster, Ag(4)Ni(2)(DMSA)(4) (DMSA = meso-2,3-dimercaptosuccinic acid) was synthesized and characteriz

37 Dimercaptosuccinic acid-coated SPIONs are internalized a

38 (7)(DMSA)(4), where DMSA represents meso-2,3-dimercaptosuccinic acid.